Neuphoria Therapeutics Inc Total Liabilities
Neuphoria Therapeutics Inc total liabilities. Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has total liabilities worth $4.11 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Neuphoria Therapeutics Inc (NEUP) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neuphoria Therapeutics Inc (1999–2026)
Total liabilities of Neuphoria Therapeutics Inc from 1999 to 2026. This chart illustrates how Neuphoria Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Neuphoria Therapeutics Inc (NEUP) long-term investment share to see how much of total assets are deployed in long-term investments.
Neuphoria Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pensonic Holdings Bhd
KLSE:9997
|
Malaysia | RM156.31 Million |
|
Alpha Microelectronics
TWO:8024
|
Taiwan | NT$35.14 Million |
|
SyntekaBio Inc
KQ:226330
|
Korea | ₩15.35 Billion |
|
Locksley Resources Ltd
AU:LKY
|
Australia | AU$1.07 Million |
|
OURGAME INT.HOL.DL-00005
F:13O
|
Germany | €34.30 Million |
|
Baid Finserv Limited
NSE:BAIDFIN
|
India | Rs2.95 Billion |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
Sweden | Skr105.25 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
Sweden | Skr147.23 Million |
Liability Composition Analysis (1999–2026)
This chart breaks down Neuphoria Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NEUP asset base.
Liquidity & Leverage Metrics
Neuphoria Therapeutics Inc Total Liabilities Ratios Explained
Neuphoria Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 27.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuphoria Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuphoria Therapeutics Inc (1999–2026)
The table below shows the annual total liabilities of Neuphoria Therapeutics Inc from 1999 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $4.11 Billion | +28108.42% |
| 2025-06-30 | $14.57 Million | +43.39% |
| 2024-06-30 | $10.16 Million | +114.21% |
| 2023-06-30 | $4.74 Million | -43.52% |
| 2022-06-30 | $8.40 Million | +67.65% |
| 2021-06-30 | $5.01 Million | -66.54% |
| 2020-06-30 | $14.97 Million | -40.58% |
| 2019-06-30 | $25.18 Million | -28.73% |
| 2018-06-30 | $35.34 Million | +5.43% |
| 2017-06-30 | $33.52 Million | -1.51% |
| 2016-06-30 | $34.04 Million | +19.40% |
| 2015-06-30 | $28.51 Million | +49.58% |
| 2014-06-30 | $19.06 Million | +71.11% |
| 2013-06-30 | $11.14 Million | +109.16% |
| 2012-06-30 | $5.32 Million | -11.19% |
| 2011-06-30 | $6.00 Million | +16.63% |
| 2010-06-30 | $5.14 Million | +5.63% |
| 2009-06-30 | $4.87 Million | -25.04% |
| 2008-06-30 | $6.49 Million | -5.76% |
| 2007-06-30 | $6.89 Million | +5.88% |
| 2006-06-30 | $6.51 Million | +33.95% |
| 2005-06-30 | $4.86 Million | +15.21% |
| 2004-06-30 | $4.22 Million | +6.87% |
| 2003-06-30 | $3.95 Million | +19.80% |
| 2002-06-30 | $3.29 Million | +904.77% |
| 2001-06-30 | $327.78K | +123.24% |
| 2000-06-30 | $146.83K | -70.98% |
| 1999-06-30 | $506.00K | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more